Clinical Trial Update: Sunitinib Malate in Treating Patients With Recurrent Transitional Cell Bladder Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial investigating sunitinib malate in recurrent transitional cell bladder cancer has been terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Transitional Cell Carcinoma of the Bladder

Drugs mentioned

• Sunitinib malate (sunitinib malate)

Snippet

Sponsor: Case Comprehensive Cancer Center | Conditions: Recurrent Bladder Cancer, Transitional Cell Carcinoma of the Bladder | Phase 2 | Status: TERMINATED | Results posted: 2019-04-04